{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T00:37:47Z","timestamp":1710463067895},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,14]]},"DOI":"10.7759\/cureus.56178","type":"journal-article","created":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T19:11:07Z","timestamp":1710443467000},"source":"Crossref","is-referenced-by-count":0,"title":["Nephrotic Syndrome Due to Sunitinib: A Rare Complication of Treatment of Renal Cell Carcinoma"],"prefix":"10.7759","author":[{"given":"Sunny","family":"Malde","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pranjal","family":"Kashiv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sushrut","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shubham","family":"Dubey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manish","family":"Balwani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Pasari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kapil N","family":"Sejpal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prasad","family":"Gurjar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60229-4","article-title":"Renal cell carcinoma","volume":"373","author":"Rini BI","year":"2009","unstructured":"Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet. 2009, 373:1119-32. 10.1016\/S0140-6736(09)60229-4","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer RJ","year":"2007","unstructured":"Motzer RJ, Hutson TE, Tomczak P, et al.. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007, 356:115-24. 10.1056\/NEJMoa065044","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.21.2516","article-title":"Sunitinib in patients with metastatic renal cell carcinoma","volume":"295","author":"Motzer RJ","year":"2006","unstructured":"Motzer RJ, Rini BI, Bukowski RM, et al.. Sunitinib in patients with metastatic renal cell carcinoma. J Am Med Assoc. 2006, 295:2516-24. 10.1001\/jama.295.21.2516","journal-title":"J Am Med Assoc"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70162-7","article-title":"Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial","volume":"10","author":"Gore ME","year":"2009","unstructured":"Gore ME, Szczylik C, Porta C, et al.. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol. 2009, 10:757-63. 10.1016\/S1470-2045(09)70162-7","journal-title":"Lancet Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2012.280","article-title":"The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines\u2014application to the individual patient","volume":"82","author":"Radhakrishnan J","year":"2012","unstructured":"Radhakrishnan J, Cattran DC. The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines\u2014application to the individual patient. Kidney Int. 2012, 82:840-56. 10.1038\/ki.2012.280","journal-title":"Kidney Int"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1159\/000241551","article-title":"Nephrotic syndrome and acute renal failure apparently induced by sunitinib","volume":"2","author":"Chen YS","year":"2009","unstructured":"Chen YS, Chen CL, Wang JS. Nephrotic syndrome and acute renal failure apparently induced by sunitinib. Case Rep Oncol. 2009, 2:172-6. 10.1159\/000241551","journal-title":"Case Rep Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.07.006","article-title":"Long-term safety of Sunitinib in metastatic renal cell carcinoma","volume":"69","author":"Porta C","year":"2016","unstructured":"Porta C, Gore ME, Rini BI, et al.. Long-term safety of Sunitinib in metastatic renal cell carcinoma. Eur Urol. 2016, 69:345-51. 10.1016\/j.eururo.2015.07.006","journal-title":"Eur Urol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1400731","article-title":"Overall survival in renal-cell carcinoma with pazopanib versus sunitinib","volume":"370","author":"Motzer RJ","year":"2014","unstructured":"Motzer RJ, Hutson TE, McCann L, Deen K, Choueiri TK. Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. N Engl J Med. 2014, 370:1769-70. 10.1056\/NEJMc1400731","journal-title":"N Engl J Med"},{"key":"ref9","article-title":"Acute Renal Tubular Necrosis","author":"Hanif MO","year":"2023","unstructured":"Hanif MO, Bali A, Ramphul K. Acute Renal Tubular Necrosis. StatPearls, Treasure Island (FL); 2023."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2010.09.012","article-title":"The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy","volume":"185","author":"Choueiri TK","year":"2011","unstructured":"Choueiri TK, Xie W, Kollmannsberger C, et al.. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol. 2011, 185:60-6. 10.1016\/j.juro.2010.09.012","journal-title":"J Urol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.6331","article-title":"Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma","volume":"26","author":"Schmidinger M","year":"2008","unstructured":"Schmidinger M, Zielinski CC, Vogl UM, et al.. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2008, 26:5204-12. 10.1200\/JCO.2007.15.6331","journal-title":"J Clin Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-145-9-200611070-00008","article-title":"Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors","volume":"145","author":"Desai J","year":"2006","unstructured":"Desai J, Yassa L, Marqusee E, et al.. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med. 2006, 145:660-4. 10.7326\/0003-4819-145-9-200611070-00008","journal-title":"Ann Intern Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/224742-nephrotic-syndrome-due-to-sunitinib-a-rare-complication-of-treatment-of-renal-cell-carcinoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T19:11:09Z","timestamp":1710443469000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/224742-nephrotic-syndrome-due-to-sunitinib-a-rare-complication-of-treatment-of-renal-cell-carcinoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,14]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.56178","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,14]]}}}